Advertisement

Drugs

, Volume 73, Issue 4, pp 371–381 | Cite as

Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure

  • Karly P. Garnock-Jones
Adis Drug Evaluation

Abstract

Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate that is specifically targeted against CD30-positive cancer cells such as those in Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). Intravenous brentuximab vedotin was associated with an overall objective response rate (primary endpoint) of 75 % in 102 patients with Hodgkin lymphoma who had relapsed after high-dose chemotherapy and autologous haematopoietic stem cell transplantation, in a noncomparative, multicentre, phase II trial. In 58 patients with relapsed systemic ALCL after at least one prior treatment, intravenous brentuximab vedotin was associated with an overall objective response rate (primary endpoint) of 86 % in a noncomparative, multicentre, phase II trial. Tumour reductions were observed in 94 % of patients with Hodgkin lymphoma and 97 % of patients with systemic ALCL, and most tumours decreased in size by >65 % and >85 %, respectively. The estimated 12-month survival rates were 89 % and 52 %, respectively. Brentuximab vedotin was generally well tolerated in these trials. The most common adverse event was peripheral neuropathy; approximately one-half of patients with this adverse event experienced complete resolution.

Keywords

Hodgkin Lymphoma Objective Response Rate Anaplastic Large Cell Lymphoma Haematopoietic Stem Cell Transplant Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

References

  1. 1.
    Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.PubMedGoogle Scholar
  4. 4.
    Banerjee D. Recent advances in the pathobiology of Hodgkin’s lymphoma: Potential impact on diagnostic, predictive, and therapeutic strategies. Adv Hematol. 2011. doi: 10.1155/2011/439456.
  5. 5.
    Dunleavy K, Piekarz RL, Zain J, et al. New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res. 2010;16(23):5608–17.PubMedCrossRefGoogle Scholar
  6. 6.
    Eichenauer DA, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011. 22 Suppl. 6:vi55–vi8.Google Scholar
  7. 7.
    National Comprehensive Cancer Network. NCCN Guidelines Version 2.2012: Hodgkin Lymphoma [online]. 2012. http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed 5 Feb 2013.
  8. 8.
    National Comprehensive Cancer Network. NCCN Guidelines Version 1.2013: Non-Hodgkin’s lymphomas [online]. 2013. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed 5 Feb 2013.
  9. 9.
    Seattle Genetics Inc. AdcetrisTM (brentuximab vedotin) for injection: US prescribing information [online]. 2012. http://www.adcetris.com/pdf/ADCETRIS_Prescribing_Information.pdf. Accessed 5 Feb 2013.
  10. 10.
    European Medicines Agency. Adcetris™ (brentuximab powder for solution for infusion): European summary of product characteristics [online]. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed 5 Feb 2013.
  11. 11.
    Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Fromm JR, McEarchern JA, Kennedy D, et al. Preclinical and clinical binding properties, internalization kinetics, and clinicopathological activity of brentuximab vedotin (SGN-35): a novel antibody drug conjugate for anaplastic large cell lymphoma and classical Hodgkin lymphoma [abstract no. 1789]. Blood. 2010; 116(21).Google Scholar
  13. 13.
    Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Seattle Genetics Inc. A phase 2 open label trial of SGN-35 for systemic anaplastic large cell lymphoma [ClinicalTrials.gov identifier NCT00866047]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://www.clinicaltrials.gov. Accessed 5 Feb 2013.
  17. 17.
    Seattle Genetics Inc. A pivotal open-label trial of SGN-35 for Hodgkin lymphoma [ClinicalTrials.gov identifier NCT00848926]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://www.clinicaltrials.gov. Accessed 5 Feb 2013.
  18. 18.
    Chen R, Gopal AK, Smith SE, et al. Long-term survival analyses of an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [abstract no. 3689]. Blood. 2012; 120(21).Google Scholar
  19. 19.
    Advani RH, Shustov AR, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update [abstract no. 443]. Blood. 2011; 118(21).Google Scholar
  20. 20.
    Pro B, Advani R, Brice P, et al. Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract no. 2745]. Blood. 2012; 120(21).Google Scholar
  21. 21.
    Seattle Genetics Inc. Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) [media release]. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1780634. Accessed 1 Feb 2013.
  22. 22.
    Seattle Genetics Inc. A phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (the AETHERA trial) [ClinicalTrials.gov identifier NCT01100502]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http://www.clinicaltrials.gov. Accessed 5 Feb 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations